CD facilitates RCT in vivo and promotes urinary cholesterol excretion

Slides:

Advertisements

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Advertisements

Fig. 1. IL-6 is associated with resistance to EGFR TKIs and is induced by stress hormones. IL-6 is associated with resistance to EGFR TKIs and is induced.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Treatment with p38γ/p38δ inhibitor shows antifungal effects in vivo

Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 6. Treatment with a DLK inhibitor is neuroprotective and reverses stress-induced gene expression changes. Treatment with a DLK inhibitor is neuroprotective.

Fig. 8. In vivo suppression of MM by CMLD

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 4 Topical application of SAAP-148 ointment eradicates acute and established infections of MRSA and A. baumannii from the skin. Topical application.

Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 5. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic mice. Antitumor efficacy of ERY974 in immunocompetent human CD3 transgenic.

Expression of CD36 and psap in a TMA of human ovarian cancer patients

Fig. 5. Pharmacological JAK2 inhibition in vivo abrogates tumor-initiating potential after chemotherapy. Pharmacological JAK2 inhibition in vivo abrogates.

Fig. 5 A competent Fc is required for the antitumor immune response.

Fig. 3. Fc fusion GDF15 molecules improve metabolic parameters in obese mice and obese cynomolgus monkeys. Fc fusion GDF15 molecules improve metabolic.

Fig. 5. Vascularization of human liver seed grafts.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 1. Serum HBsAg, HBcrAg, and HBeAg reduction in human patients treated with a single dose of ARC-520. Serum HBsAg, HBcrAg, and HBeAg reduction in human.

Fig. 5. In vivo characterization of adipogenesis by CT.

Fig. 5 Combination intravenous reovirus and checkpoint inhibition in an orthotopic syngeneic brain tumor model. Combination intravenous reovirus and checkpoint.

Fig. 4. MATE1 transcription in RCC.

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Fig. 6 ROC curves of mCCNA1 and mVIM assayed on esophageal balloon samplings of the distal esophagus. ROC curves of mCCNA1 and mVIM assayed on esophageal.

Fig. 6. Apoptotic MSCs exert in vivo immunosuppression in a TH2-type inflammation model in the absence of cytotoxic cells. Apoptotic MSCs exert in vivo.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Fig. 4. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in vivo. BET inhibition sensitizes HR-proficient tumors to PARPi treatment in.

Fig. 7 BRD0705 impairs colony formation in AML cell lines and patient cells and shows in vivo efficacy in multiple AML mouse models. BRD0705 impairs colony.

Fig. 7. KIF11 informs patient prognosis, and targeting improves survival in a preclinical model. KIF11 informs patient prognosis, and targeting improves.

Fig. 1. Map showing the study catchment area in the East of England.

Fig. 8 Combining M7824 with radiation or chemotherapy enhances antitumor efficacy. Combining M7824 with radiation or chemotherapy enhances antitumor efficacy.

Fig. 5 Local gel scaffold for T cell memory response.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 4. Improved tumor response to docetaxel in TNBC and trastuzumab in HER2-amplified PDX models with the addition of S Improved tumor response.

Fig. 7. Therapeutic effects of hiPSC-EPO protein on renal anemia in adenine-treated mice. Therapeutic effects of hiPSC-EPO protein on renal anemia in adenine-treated.

Fig. 8 SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and in vivo. SQLE inhibitor terbinafine suppresses NAFLD-HCC growth in vitro and.

Fig. 5. Nutlin-3 treatment rescues the proliferation and differentiation of NPCs in vitro. Nutlin-3 treatment rescues the proliferation and differentiation.

Comparison of therapeutic efficacies of C12G6 and other bnAbs in mice

Stroke induces atheroprogression via the RAGE-signaling pathway

Fig. 4 PD-L1 expression is found in the spleen and the BM of mice transplanted with JAK2V617F-transduced bone marrow. PD-L1 expression is found in the.

Fig. 7. mRIPO therapy restricts tumor growth and produces antigen-specific antitumor immunity. mRIPO therapy restricts tumor growth and produces antigen-specific.

Fig. 4. The effect of single-dose rozanolixizumab on the concentration of IgG subtypes in healthy subjects. The effect of single-dose rozanolixizumab on.

Fig. 6 Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing mice. Anticancer effects in PyMT-MMTV syngeneic and MDA-MB-231 xenograft-bearing.

Fig. 2. Exposure of both TCR and CAR antigens diminishes efficacy of CAR8 but not CAR4 cells. Exposure of both TCR and CAR antigens diminishes efficacy.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Fig. 4 Surgery initiates a systemic inflammatory response that triggers the outgrowth of distant immunogenic tumors and can be inhibited by perioperative.

Fig. 1. In vivo fates of patient-derived AML cells defined by mutational profile. In vivo fates of patient-derived AML cells defined by mutational profile.

Bexarotene is neuroprotective in mouse and human HD neurons in vitro

Fig. 6 Innate and adaptive immunity, but not ADCC, contributes to M7824 antitumor activity. Innate and adaptive immunity, but not ADCC, contributes to.

Stroke induces inflammatory activation of the aortic endothelium

Decreased weight and adiposity is transmissible via the gut microbiota

Fig. 2 Activation of freshly isolated CD4+ T cells from HIV-infected patients on ART results in successive increases in elongated, polyadenylated, and.

Fig. 4. Local application of FR provides prolonged protection against Gq-dependent airway constriction in normal and OVA-sensitized mice in vivo. Local.

Fig. 5 ALRN-6924 shows robust antileukemic activity in primary AML cells and in vivo. ALRN-6924 shows robust antileukemic activity in primary AML cells.

Fig. 5 Treatment with an OX40 agonist antibody of 3-week-old HBVtgRag−/− mice or mice with chronic HBV disease results in an altered immune response to.

Fig. 6. Eradication of FLT3-ITD+ AML cells in vivo through combined inhibition of kinase and antiapoptotic pathways. Eradication of FLT3-ITD+ AML cells.

Fig. 4. Clearance of 12-mer-1 from a nonhuman primate model.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Filipin staining of marginal gyrus of cerebral cortex in NPC cats

Colonization in tumor models and different modes of administration

CD mediates metabolism and efflux of crystal-derived cholesterol

Fig. 2 PK dosing results. PK dosing results. (A) Plasma concentration of hPTH(1–34) versus time after release of 40-μg dose from implanted microchip device.

Fig. 3. In vivo tumor responses are mechanism of action–specific and concentration-dependent. In vivo tumor responses are mechanism of action–specific.

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

Presentation transcript:

Fig. 6. CD facilitates RCT in vivo and promotes urinary cholesterol excretion. CD facilitates RCT in vivo and promotes urinary cholesterol excretion. (A) BMDMs from WT or LXRα−/−β−/− mice were loaded with 100 μg of D6-CC per 1 × 106 cells and injected into the peritoneum of WT mice. Subsequently, mice were treated subcutaneously with CD (2 g kg) or vehicle control (n = 4 per group). (B and C) D6-cholesterol content in feces and urine collected every 3 hours over 30 hours after CD injection. Data are shown as total area under the curve (AUC) of excreted D6-cholesterol pooled from the mice within a group per time point. (D) Urine samples collected from three individual NPC1 patients upon intravenous application of CD for specific treatment of NPC. Urine cholesterol concentration was determined by GC-MS-SIM and normalized to urine creatinine excretion. Sebastian Zimmer et al., Sci Transl Med 2016;8:333ra50 Published by AAAS